v3.25.4
Earnings per Share (Tables)
12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
Summary of Earnings Per Share, Basic and Diluted
The following table sets forth the reconciliation of the numerator and denominator used to calculate basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts):

Years Ended December 31,
202520242023
Numerator
Consolidated net income$1,324,192 $1,330,813 $1,700,088 
Less: Net income attributable to the Continuing Investors Partnerships231,260 276,893 392,726
Less: Net income attributable to the Legacy Investors Partnerships232,524 194,937 172,528
Less: Net income attributable to the Founder’s Equity(1)
60,243 — — 
Less: Net income attributable to the RP Holdings Class E Interests Holders29,218 — — 
Net income attributable to Royalty Pharma plc - basic770,947 858,983 1,134,834
Add: Reallocation of net income attributable to the Continuing Investors Partnerships from the assumed exchanges of Class B ordinary shares231,260 276,893 392,726
Add: Reallocation of net income attributable to the Holders of RP Holdings Class E Interests from the assumed exchanges of eligible Class B ordinary shares3,315 — — 
Net income attributable to Royalty Pharma plc - diluted$1,005,522 $1,135,876 $1,527,560 
Denominator
Weighted average Class A ordinary shares outstanding - basic429,801 448,185 447,601
Add: Dilutive effects as shown separately below
Assumed exchanges of Class B ordinary shares by Continuing Investors Partnerships132,616 145,911 155,292
Unvested RSUs14 12 7
Shares contingently issuable for the Equity Performance Awards270 — — 
Assumed exchanges of eligible Class B ordinary shares by Holders of RP Holdings Class E Interests1,754 — — 
Weighted average Class A ordinary shares outstanding - diluted564,455 594,108 602,900
Earnings per Class A ordinary share - basic$1.79 $1.92 $2.54 
Earnings per Class A ordinary share - diluted$1.78 $1.91 $2.53 
(1)Amounts represent the entirety of the EPAs prior to the Internalization and only the Founder’s Equity portion after the Internalization.